Summary
This review collected every study it could find, up to September 2023, on puberty blockers for young people with gender distress, and rated how trustworthy the evidence was. Only 10 studies qualified, and none was a randomised trial, where people are assigned to treatment by chance. The studies were small and often missing results for many people. Every result on mental health, gender distress and bone density was rated very low quality. Bone density seemed lower after treatment, and nearly all young people went on to cross-sex hormones. The authors conclude we cannot tell whether blockers help or harm, and call for better studies. Its findings match other independent reviews, including those for England's Cass Review. But it was funded by SEGM, a group critical of youth transition, it only searched English-language studies, and it misses newer studies.
Key findings
- 回顧找到 10 項研究:3 項比較了使用與未使用阻斷劑的年輕人,7 項只在前後測量同一群人。
- 沒有隨機試驗,也就是以抽籤的方式分配治療的試驗。
- 所有關於性別困擾、日常功能和憂鬱的證據都被評為極低品質,因此無法排除有益處或有傷害。
- 在比較研究中,12 個月後使用阻斷劑者的日常功能分數看起來稍好一些,但結果非常不確定,可能代表從稍差到好很多的任何情況。
- 使用阻斷劑後,髖部和脊椎的骨質密度落後於同齡者,不過這項證據也被評為非常薄弱。
- 在兩項研究中,92% 使用阻斷劑的年輕人在 1 至 3 年內接續使用跨性別荷爾蒙。
- 數項研究只有不到半數年輕人的結果,也沒有一項適當考慮治療、其他心理健康狀況或家庭支持。
- 作者呼籲進行仔細的研究,及時往前追蹤年輕人,並且在合乎倫理的情況下進行隨機試驗。
Abstract
Aim Gender dysphoria (GD) refers to the psychological distress associated with the incongruence between one's sex and one's gender identity. To manage GD, individuals may delay the development of primary and secondary sex characteristics with the use of puberty blockers. In this systematic review, we assess and summarise the certainty of the evidence about the effects of puberty blockers in individuals experiencing GD. Methods We searched Medline, Embase, PsychINFO, Social Sciences Abstracts, LGBTQ+ Source and Sociological Abstracts from inception to September 2023. We included observational studies comparing puberty blockers with no puberty blockers in individuals aged <26 years experiencing GD, as well as before-after and case series studies. Outcomes of interest included psychological and physical outcomes. Pairs of reviewers independently screened articles, abstracted data and assessed risk of bias. We performed a meta-analysis and assessed the certainty of a non-zero effect using the grading of recommendations assessment, development and evaluation (GRADE) approach. Results We included 10 studies. Comparative observational studies (n=3), comparing puberty blockers versus no puberty blockers, provided very low certainty of evidence on the outcomes of global function and depression. Before-after studies (n=7) provided very low certainty of evidence addressing gender dysphoria, global function, depression, and bone mineral density. Conclusions There remains considerable uncertainty regarding the effects of puberty blockers in individuals experiencing GD. Methodologically rigorous prospective studies are needed to understand the effects of this intervention. Trial registration number PROSPERO CRD42023452171.
Conclusion
The best available evidence reporting the effects of puberty blockers in individuals with GD was mostly very low certainty and therefore we cannot exclude the possibility of benefit or harm. There was evidence available for the outcomes of global function, depression, GD, bone mineral density and progression to gender affirming hormone therapy. High certainty evidence from prospective cohort studies and, if ethical, RCTs, is needed to understand the short and long term effects of puberty blockers in individuals experiencing GD.